1,995 reports of this reaction
3.4% of all THALIDOMIDE reports
#3 most reported adverse reaction
PLASMA CELL MYELOMA is the #3 most commonly reported adverse reaction for THALIDOMIDE, manufactured by Celgene Corporation. There are 1,995 FDA adverse event reports linking THALIDOMIDE to PLASMA CELL MYELOMA. This represents approximately 3.4% of all 58,680 adverse event reports for this drug.
THALIDOMIDE has an overall safety score of 95 out of 100. Patients taking THALIDOMIDE who experience plasma cell myeloma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PLASMA CELL MYELOMA is moderately reported among THALIDOMIDE users, representing a notable but not dominant share of adverse events.
In addition to plasma cell myeloma, the following adverse reactions have been reported for THALIDOMIDE:
The following drugs have also been linked to plasma cell myeloma in FDA adverse event reports:
PLASMA CELL MYELOMA has been reported as an adverse event in 1,995 FDA reports for THALIDOMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PLASMA CELL MYELOMA accounts for approximately 3.4% of all adverse event reports for THALIDOMIDE, making it one of the most commonly reported side effect.
If you experience plasma cell myeloma while taking THALIDOMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.